MedTrace Logo

Afatinib Genomic Landscape

NCT02491775 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2018-03-05

No results posted yet for this study

Summary

The investigators propose to conduct a pilot feasibility study of single agent afatinib in patients with previously untreated metastatic EGFR (epidermal growth factor receptor) mutant adenocarcinoma of the lung (NSCLC = non-small cell lung cancer) with the sole purpose of characterizing the genomic landscape before afatinib and at the time of disease progression.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Ramaswamy Govindan, M.D. · Washington University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-11
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02491775 on ClinicalTrials.gov